-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Considerations for Next Therapy After ANTI CD38 Monoclonal Antibodies Used as First Line

Program: Education Program
Session: How Do We Improve Outcomes in Relapsed and Refractory Multiple Myeloma in 2023?
Hematology Disease Topics & Pathways:
Research, clinical trials, Clinical Research, Combination therapy, Therapies, therapy sequence, Minimal Residual Disease
Sunday, December 10, 2023, 9:30 AM-10:45 AM

Monique A Hartley-Brown, MD

Medical Oncology, DFCI, Boston, MA

Disclosures: Hartley-Brown: Janssen: Consultancy, Honoraria; Karyopharm: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria; GlaskoSmith Kline: Consultancy, Honoraria; Bristol Myers Squibb/Celgene: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria.

OffLabel Disclosure: